Abstract
In March 2021, the FDA approved idecabtagene vicleucel, a chimeric antigen receptor T-cell therapy targeting the B-cell maturation antigen (BCMA), for......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
